Vertex Pharmaceuticals Establishes Wholesale Acquisition Cost For Alyftrek In U.S. Of $370,269 On Annual Basis ($28,404 Per 28-day Pack)

+1.37%

Vertex Pharmaceuticals Incorporated

VRTX

452.04

+1.37%

On December 20, 2024, the U.S. Food and Drug Administration approved ALYFTREK™ (vanzacaftor/tezacaftor/deutivacaftor) for the treatment of cystic fibrosis in people 6 years and older who have at least one F508del mutation or another mutation in the cystic fibrosis transmembrane conductance regulator gene that is responsive to ALYFTREK.

We have established a wholesale acquisition cost for ALYFTREK in the United States of $370,269 on an annual basis ($28,404 per 28-day pack).

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.